Telix gets FDA nod for gallium injection prep kit

By staff writers

March 16, 2023 -- The U.S. Food and Drug Administration (FDA) has cleared Telix Pharmaceuticals' gallium-68 (Ga-68) gozetotide injection (Illuccix) preparation kit.

To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent; the Illuccix kit identifies patients who are candidates for the only FDA-approved prostate-specific membrane antigen (PSMA)-directed radioligand therapy, Pluvicto, according to the firm.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking